Contribution of voriconazole N‐oxide plasma concentration measurements to voriconazole therapeutic drug monitoring in patients with invasive fungal infection
| العنوان: | Contribution of voriconazole N‐oxide plasma concentration measurements to voriconazole therapeutic drug monitoring in patients with invasive fungal infection |
|---|---|
| المؤلفون: | Christelle Boglione‐Kerrien, Jeff Morcet, Lucie‐Marie Scailteux, François Bénézit, Christophe Camus, Jean‐Baptiste Mear, Jean‐Pierre Gangneux, Eric Bellissant, Camille Tron, Marie‐Clémence Verdier, Florian Lemaitre |
| المساهمون: | CHU Pontchaillou [Rennes], Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), École des Hautes Études en Santé Publique [EHESP] (EHESP) |
| المصدر: | Mycoses Mycoses, 2023, ⟨10.1111/myc.13570⟩ |
| بيانات النشر: | Wiley, 2023. |
| سنة النشر: | 2023 |
| مصطلحات موضوعية: | phenotyping, Infectious Diseases, pharmacokinetic variability, metabolic ratio, therapeutic drug monitoring, voriconazole N-oxide, [SDV]Life Sciences [q-bio], voriconazole, Dermatology, General Medicine, Antifungal, invasive fungal infection |
| الوصف: | International audience; BACKGROUND: Voriconazole (VRC), a widely used triazole antifungal, exhibits significant inter- and intra-individual pharmacokinetic variability. The main metabolite voriconazole N-oxide (NOX) can provide information on the patient’s drug metabolism capacity. OBJECTIVES: Our objectives were to implement routine measurement of NOX concentrations and to describe the metabolic ratio (MR), and the contribution of the MR to VRC therapeutic drug monitoring (TDM) by proposing a suggested dosage-adjustment algorithm. PATIENTS AND METHODS: Sixty-one patients treated with VRC were prospectively included in the study, and VRC and NOX levels were assayed by LC-MS/MS. A mixed logistic model on repeated measures was implemented to analyze risk factors for the patient’s concentration to be outside the therapeutic range. RESULTS: Based on 225 measurements, the median and interquartile range were 2.4 μg/mL (1.2; 4.2), 2.1 μg/mL (1.5; 3.0), and 1.0 (0.6; 1.9) for VRC, NOX, and the MR, respectively. VRC C(min) 1.15 and |
| تدمد: | 1439-0507 0933-7407 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65918c64f88993ec6068558c9e2dc0aaTest https://doi.org/10.1111/myc.13570Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....65918c64f88993ec6068558c9e2dc0aa |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14390507 09337407 |
|---|